ArticleFrontiers in medicine2025
The C-reactive protein-to-albumin ratio as a diagnostic biomarker for rheumatoid arthritis: a cross-sectional NHANES analysis.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Comparison and validation of systemic immune-inflammation index, C-reactive protein/albumin ratio, and C-reactive protein-albumin-lymphocyte index for assessing disease activity in rheumatoid arthritis.Clinical rheumatology · 2026Article
- The C-Reactive Protein/Albumin Ratio Predicts In-Hospital Mortality Across Age Groups.Nutrients · 2026Article
- C-reactive Protein/Albumin Ratio as a Predictive Inflammatory Marker for Postoperative Systemic Inflammatory Response Syndrome and/or Sepsis in Polytraumatized Patients in ICU.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Rheumatoid arthritis (RA) is a chronic inflammatory disorder that leads to joint damage, cartilage and bone destruction, and functional disability. The C-Reactive Protein to Albumin Ratio (CAR), an emerging biomarker reflecting systemic inflammation and nutritional status, has demonstrated prognostic value in various diseases. However, its utility in predicting clinical outcomes in RA patients remains underexplored, warranting further investigation to assess its potential role in disease management and prognosis. This cross-sectional study investigates the potential relationship between CAR and RA in United States adults, develops a clinical prediction model, and validates its effectiveness. Objective: To investigate the association between the CAR and RA using data from the National Health and Nutrition Examination Survey (NHANES). Methods: This large-scale, cross-sectional study analyzed data from the NHANES database between 1999 and 2018 (excluding 2011-2014). The CAR was calculated as the ratio of C-reactive protein (CRP) to albumin (ALB) levels. RA status was identified through self-reported questionnaire data. Weighted multivariate regression models and subgroup analyses were used to examine the association between CAR and RA. Restricted cubic splines (RCS) were employed to evaluate potential non-linear relationships, and sensitivity analyses were conducted to assess the robustness of the results. Least absolute shrinkage and selection operator (LASSO) were utilized for variable selection in the prediction model. Decision curve analysis (DCA) and receiver operating characteristic (ROC) curve analysis were applied to assess the predictive performance of the models. Results: This study included a total of 20,733 patients, among whom 1,744 individuals (4.95%) were diagnosed with RA. After controlling for all covariates, the results of multivariate logistic regression analysis indicated a statistically significant correlation between higher Ln(CAR) levels and the increased incidence of RA (OR:1.77 (95% CI, 1.39-2.25); Conclusion: These findings suggest that CAR may serve as a promising inflammatory biomarker for predicting the presence of RA. In the RA prediction model incorporating CAR, we validated the effectiveness and clinical utility of this model, providing evidence that CAR can serve as a biomarker for RA risk prediction. Further prospective studies are warranted to validate its clinical utility in RA risk stratification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.